FUJIFILM Diosynth Biotechnologies Enters Into an Agreement with Argenx to Manufacture Efgartigimod, a monoclonal antibody (mAb) for the Treatment of Severe Autoimmune Diseases
October 27, 2022 01:05 ET
|
FUJIFILM Holdings America Corporation
HILLERØD, Denmark, Oct. 27, 2022 (GLOBE NEWSWIRE) -- FUJIFILM Diosynth Biotechnologies, a world leading contract development and manufacturing organization for biologics, vaccines, and advanced...
Approbation de la colchicine à faible dose par Santé Canada pour les maladies cardiovasculaires basée sur l’étude COLCOT
August 27, 2021 07:00 ET
|
Institut de Cardiologie de Montréal (ICM)
Le médicament MYINFLAMC 0.5 mg est approuvé par Santé Canada pour la réduction des risques cardiovasculaires chez les patients atteints d’une maladie coronarienne MONTRÉAL, 27 août 2021...
Health Canada approval of low-dose colchicine for cardiovascular disease based on the COLCOT study
August 27, 2021 07:00 ET
|
Montreal Heart Institute
MONTREAL, Aug. 27, 2021 (GLOBE NEWSWIRE) -- People with coronary disease now have a new treatment option to reduce the risk of cardiovascular events. Health Canada has issued a Notice of Compliance...